JUN and skin basal cell carcinoma: Pre-clinically, inhibition of BCC cell proliferation by the JNK inhibitor SP600125 indicates that targeting the JNK-JUN pathway may represent an effective strategy to interfere with YAP-driven tumorigenesis (81).